News

It's Too Soon To Upgrade Stryker Corporation

Stryker Corporation remains a global leader in medical technologies, with strong segment breadth and robust product innovation. Read more on SYK stock here.

SeekingAlpha·11:02SYK▼−2.3%

Countdown to Stryker (SYK) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS

Get a deeper insight into the potential performance of Stryker (SYK) for the quarter ended September 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.

Yahoo·08:15SYK▼−2.3%

Stryker completes acquisition of ZuriMED to enhance its shoulder offering

Portage, Michigan, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Stryker has completed its acquisition of ZuriMED, adding the FiberLocker System to its Sports Medicine portfolioThe acquisition adds a commercialized rotator cuff augmentation technology to Stryker’s shoulder portfolioThe addition expands Stryker’s ability to support shoulder specialists across sports medicine and shoulder care Stryker (NYSE:SYK), a global leader in medical technologies, announced it has completed the acquisition of ZuriMED, a

Yahoo·08:00SYK▼−2.3%

Stryker (SYK) Tests Its Valuation After Sonopet 3 Clearance

Stryker (SYK) just received 510(k) clearance from the U.S. Food and Drug Administration for Sonopet 3, a new ultrasonic bone and soft tissue removal platform shaped by extensive surgeon feedback. For context, Stryker’s recent 1 month share price return of 11.63% and 7 day move of 4.72% have come after a tougher patch, with the stock down 7.02% over 3 months and its 1 year total shareholder return declining 18.95%. Meanwhile, the 3 year and 5 year total shareholder returns of 22.32% and 20.59%...

Yahoo·11:16SYK▼−2.3%

Stryker (SYK) Stock May Trade At A Discount Despite FDA Clearance

Stryker has had a mixed run, with the share price up 22.3% over three years but still showing declines over the past year. This puts fresh focus on whether the current US$307.08 level lines up with the cash the business can generate. With new products, fresh partnerships and legal scrutiny all in play, the question for anyone looking at the stock is how those moving parts feed into its underlying cash flow story. The 22.3% gain over three years means a holder today is looking at a stock...

Yahoo·23:18SYK▼−2.3%

Stryker (SYK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Stryker (SYK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo·09:00SYK2.3%

PAHC or SYK: Which Is the Better Value Stock Right Now?

PAHC vs. SYK: Which Stock Is the Better Value Option?

Yahoo·10:40SYK▼−2.3%

Stryker's Sonopet 3 Secures FDA Clearance to Improve Surgical Accuracy

SYK's Sonopet 3 secures FDA clearance, promising enhanced surgical precision and efficiency, with a full commercial launch expected later this fall.

Yahoo·07:14SYK▼−2.3%

Is Stryker Corp. (SYK) Positioned for Above-Market Growth?

Diamond Hill Capital, a First Eagle Investment Management company, issued its Q3 2026 investor letter for its “Large Cap Strategy”. The letter can be downloaded here. The Strategy returned 3.18% (net of fees) in the quarter, outperforming the 2.61% return of the Russell 1000 Value Index. Key positive contributors included stock selection in information technology, an underweight in […]

Yahoo·10:40SYK▼−2.3%

Stryker Enters Soft-Tissue Robotics With $400 Million CMR Deal

SYK's $400 million investment in CMR Surgical marks its entry into soft-tissue robotics, expanding its surgical portfolio with Versius technology.

Yahoo·09:15SYK▼−2.3%

Is FDA-Cleared Sonopet 3 Transforming the Investment Case for Stryker’s Surgical Platform Strategy (SYK)?

Earlier this month, Stryker received FDA 510(k) clearance for Sonopet 3, its new ultrasonic bone and soft tissue removal platform, incorporating surgeon-driven enhancements in power, precision, workflow integration and connectivity ahead of a planned full commercial launch later this fall. The clearance underscores Stryker’s push to pair advanced surgical hardware with digital tools such as its RISE connected workflow and Pulse Control technology, potentially deepening its presence in...

Yahoo·15:09SYK▼−2.3%

What Is Stryker (SYK) Really Getting From Its $400 Million Robotics Deal?

Stryker (NYSE:SYK) agreed to invest US$400m in CMR Surgical in a deal focused on soft-tissue robotic surgery. The agreement grants Stryker exclusive U.S. rights to commercialize CMR's Versius robotic surgery platform. Stryker also secured an exclusive option to acquire CMR Surgical, extending its reach beyond orthopedics and MedSurg. The US$400m CMR Surgical deal, which includes U.S. Versius rights and an acquisition option, is only one piece of the Stryker story. We have also flagged 2...

Yahoo

Earnings Preview: What To Expect From Stryker Corporation’s Report

Medtech company Stryker Corporation will announce its Q3 earnings on Oct. 29.

Yahoo·10:09SYK▼−2.3%

Stryker launches Sonopet® 3, delivering greater power and precision in ultrasonic tissue removal

Stryker (NYSE: SYK), a global leader in medical technologies, announced today that Sonopet 3, its latest ultrasonic bone and soft tissue removal platform, has received 510(k) clearance from the U.S. Food and Drug Administration.

Yahoo·09:03SYK▼−2.3%

Stryker Makes $400 Million Robotic Surgery Bet

Stryker invests $400M in CMR Surgical to expand into soft-tissue robotics and secure exclusive U.S. sales rights for the Versius system.

Benzinga·09:11SYK▼−2.3%

Stryker: Q2 Recovery And Portfolio Expansion Strengthen The Operating Story

Stryker rebounded in 2Q26, with operating momentum restored after the prior quarter’s cybersecurity disruption. Learn why SYK stock is a buy.

SeekingAlpha·23:11SYK▼−2.3%

3 Reasons Investors Watch Stryker (SYK)

Over the past six months, Stryker’s shares (currently trading at $277.82) have posted a disappointing 20% loss, well below the S&P 500’s 12.8% gain. This may have investors wondering how to approach the situation.

Yahoo·17:51SYK▼−2.3%

Stryker invests $400m into CMR Surgical; secures future buyout option

Stryker's pact with UK-headquartered CMR Surgical gives it a route into the soft tissue robotic surgery market.

Yahoo·12:48SYK▼−2.3%

Smoke Evacuation Systems Market Forecasts Growth from $0.20B (2025) to $0.30B by 2031, Profiling CONMED, Medtronic, Stryker & Becton Dickinson

The global smoke evacuation systems market is forecast to grow from USD 0.20 billion in 2025 to USD 0.30 billion by 2031, at a 7.5% CAGR. Growth is driven by rising minimally invasive, electrosurgical and laparoscopic procedures, stricter surgical smoke safety guidance, and demand for better operating room air quality. Smoke evacuation pencils and wands lead the product segment, while laparoscopic surgery holds the largest application share. The US is expected to record North America’s fastest g

Yahoo·06:24SYK▼−2.3%

Medical Robots Market Forecasts Growth from $20.6B (2026) to $41.7B by 2031, Profiling Intuitive Surgical, Stryker, Zimmer Biomet & Medtronic

The global medical robots market is projected to grow from USD 20.6 billion in 2026 to USD 41.7 billion by 2031, at a 15.1% CAGR. Growth is driven by demand for minimally invasive surgery, healthcare automation, precision procedures, and advances in AI-powered surgical, rehabilitation, radiosurgery, hospital, and pharmacy robots. Robotic systems will hold the largest market share, while surgical robots will lead by type. Ambulatory surgery centers are set for the fastest end-user growth, and Asi

Intuitive Surgical vs. Stryker: Which MedTech Stock Is the Better Buy Now?

ISRG's rapid procedure growth, expanding robotics ecosystem and recurring revenues highlight its growth path amid MedTech shifts.

Yahoo·11:31SYK▼−2.3%

Here's Why You Should Hold Stryker Stock in Your Portfolio for Now

SYK's resilient demand, Mako robotics growth and margin gains support its outlook despite cyber and supply disruptions.

Yahoo·11:14SYK▼−2.3%

Minimally Invasive Robotic Surgical System Market Global Report 2026: Benchmark Intuitive Surgical, Johnson & Johnson, Medtronic, Stryker and Zimmer Biomet Now

Players: Intuitive Surgical, Johnson & Johnson, Medtronic, Stryker, Zimmer Biomet. Profile covers competitors, segments, regional shares, trends and opportunities. Minimally Invasive Robotic Surgical System Market Minimally Invasive Robotic Surgical System Market Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "Minimally Invasive Robotic Surgical System Market Global Report 2026" has been added to ResearchAndMarkets.com's offering. Minimally Invasive Robotic Surgical System Market to Reach $18.15 Bil

Yahoo·06:50SYK▼−2.3%

Stryker (SYK) Foot And Ankle Push Keeps Undervalued Narrative In Focus

Why Stryker’s new Foot & Ankle push matters for shareholders Stryker (SYK) is putting fresh attention on its Foot & Ankle franchise, rolling out new planning tools and limb reconstruction hardware at the 2026 AOFAS meeting in Seattle. The spotlight is on Prophecy Surgical Planning, now linked to the Incompass Total Ankle System, and on the Hoffmann LRF smartHEX platform, which extends the company’s reach into complex deformity correction supported by mobile software. Set against this product...

Yahoo·12:16SYK▼−2.3%

THINK Surgical Appoints Rick McDowell as Vice President, Sales

THINK Surgical, Inc., an innovator in the field of orthopedic surgical robots, today announced that Rick McDowell has joined the company as Vice President, Sales. In this role, Rick will report to Chris Marrus, Executive Vice President, and will lead THINK Surgical's national sales organization, driving market strategy and growth as the company continues to scale its commercial operations.

Yahoo·10:46

Stryker (SYK) Expanded Its Foot And Ankle Portfolio

Stryker (NYSE:SYK) announced new Foot & Ankle portfolio updates, including expanded Prophecy Surgical Planning, at a major industry meeting. The company introduced the Hoffmann LRF smartHEX system, aimed at limb reconstruction and patient connectivity in complex cases. Expanded planning tools and patient specific technologies are intended to support surgeon decision making in ankle replacement procedures. The Prophecy Surgical Planning expansion and Hoffmann LRF smartHEX launch sit alongside...

Yahoo·06:14SYK▼−2.3%

Treace Medical Looks Unlikely To Recover, A Founder-Led Broken Growth Story

Treace Medical outlook: revenue declines, Lapiplasty losing share, margins compressing, and EBITDA delayed. Click for more on TMCI stock.

SeekingAlpha·01:06

3 of Wall Street’s Favorite Stocks Worth Investigating

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.

Yahoo·09:36

Canaccord Genuity Maintains Buy on Stryker, Lowers Price Target to $385

Canaccord Genuity analyst Kyle Rose maintains Stryker (NYSE:SYK) with a Buy and lowers the price target from $400 to $385.

Benzinga·04:35SYK▼−2.3%

Why BSX Stock Lost More Than Half Its Value While Sales Kept Rising

Boston Scientific (BSX) has fallen about 54% since late December 2025, and it now sits at $43.91, just above a 52-week low of $42.63. Device peers were mixed over the same nine months: Abbott lost about 17%, Medtronic barely moved, and Johnson & Johnson rose about 32%. The market repriced Boston Scientific's growth rate after management concentrated its guidance cut in two core product lines.

Yahoo·12:31

Stryker Facing Promising Setup Next Year, Trading Upside Limited in 2026, RBC Says

Stryker (SYK) will likely see an acceleration story in 2027, with high single digit growth achievabl

Yahoo·11:14SYK▼−2.3%

Stryker Expands Foot & Ankle Innovation With Prophecy and smartHEX

Global Surgical Robots Market to Reach $10.6 Billion in 2026, Driven by AI Integration and Minimally Invasive Surgery

Report Features In-Depth Profiles of Abbott, Great Robotics, Intuitive Surgical, Johnson & Johnson, Medtronic, Panasonic, Renishaw, Siemens Healthineers, Smith+Nephew, Stryker, Zimmer Biomet, and FreehandDublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The "Surgical Robots Market by Offering of Surgical Robot Developers, Deployment Model, Type of Surgical Procedure Supported, Application Area, End Users and Key Geographical Regions - Trends and Forecast Till 2035" has been added to ResearchAndMarkets.

Yahoo·04:21SYK▼−2.3%

Schedule update: Stryker to participate in the 2026 Wells Fargo Healthcare Conference

Portage, Michigan, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the 2026 Wells Fargo Healthcare Conference on Tuesday, September 8, 2026, at the Encore Boston Harbor, as previously reported. Preston Wells, Vice President, Chief Financial Officer and Nick Mead, Vice President, Investor Relations will now participate in a fireside chat session at 10:15 a.m. (Eastern time). A simultaneous live audio webcast and replay of the session can be accessed at Stryker - Events &

Yahoo·19:32SYK▼−2.3%

Stryker (SYK) is Buying ZuriMED. Can FiberLocker Strengthen its Shoulder Portfolio?

Stryker Corporation (NYSE:SYK) signed a definitive agreement to acquire privately held ZuriMED, which would add the commercialized FiberLocker System to its shoulder portfolio upon closing. FiberLocker is designed to reinforce rotator-cuff repairs by strengthening the connection between a surgical patch and tendon tissue. The transaction remains subject to customary closing conditions, while the purchase price […]

Yahoo·

Intuitive Surgical Vs. Stryker: Wall Street Loves Both But One Has a Quiet Advantage That Will Make Investors Money

Both Intuitive Surgical and Stryker just posted their fifth straight earnings beat, and Wall Street is cheering for both. But a structural difference buried inside their business models quietly separates a compounder from a cyclical recovery story.

Yahoo·10:45SYK▼−2.3%

Medical Devices & Supplies - Diversified Stocks Q2 Teardown: Stryker (NYSE:SYK) Vs The Rest

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Stryker (NYSE:SYK) and the best and worst performers in the medical devices & supplies - diversified industry.

Yahoo·17:32SYK▼−2.3%

ISRG Stock: The Best House On The Block Costs The Most

In the world of robotic surgery, one company is both the undisputed leader and the most expensive option, forcing investors to ask if operational excellence is worth the premium.

Yahoo·16:37

The Wide Divide Priced Into Boston Scientific Stock

The market's valuation reflects a wide breadth of potential outcomes for the company, exposing shareholders to the full magnitude of that underlying risk.

Yahoo·14:52

Enovis inks eCential takeover to develop surgical ortho robots

The orthopedics specialist aims to launch a knee robot in late 2028, followed by a shoulder robot in 2029.

Yahoo·07:00

Stryker (SYK) Wins FDA Nod And Completes First Procedure With New Surgery Software

Stryker (NYSE:SYK) received FDA De Novo authorization for its SportSuite Vision software on Apple Vision Pro in a clinical setting. The company reported completion of the first surgical procedure using SportSuite Vision in an operating room environment. The software introduces augmented reality and spatial computing tools into surgical workflows and operating room visualization. The authorization marks a regulatory milestone for Stryker in mixed reality applications for healthcare. This...

Yahoo·14:06SYK▼−2.3%

Stryker to add rotator cuff repair tech with ZuriMED buy

Rotator cuff augmentation is one of the fastest-growing areas in sports medicine, according to Stryker.

Yahoo·14:02SYK▼−2.3%

Stryker to Acquire ZuriMED to Expand Its Shoulder Care Portfolio

SYK's planned ZuriMED acquisition adds the FiberLocker System, aiming to strengthen its shoulder portfolio and rotator cuff care capabilities.

Yahoo·11:10SYK▼−2.3%

Intuitive Surgical Stock Has Fallen While Its Operating Margin Keeps Widening

With US procedure growth slowing and the shares well below their high, the operating margin has widened in each of the last three years.

Yahoo·15:01

US$100 Million Defense Contract Win Might Change The Case For Investing In Stryker (SYK)

Stryker’s sales unit in Michigan previously secured a US$100.00 million contract modification from the U.S. Defense Logistics Agency, underscoring its role as a key supplier to government healthcare and logistics systems. This award highlights the importance of stable government contracting as a complement to Stryker’s hospital and surgical product revenue mix. We’ll now examine how this sizable Defense Logistics Agency contract influences Stryker’s investment narrative, particularly its...

Yahoo·13:11SYK▼−2.3%

Stryker (SYK) Wins $100 Million Contract, Is It Still Below Fair Value?

Stryker (SYK) is back in focus after its Stryker Sales unit secured a $100 million contract modification from the US Defense Logistics Agency, a development that coincided with a 2.7% share price move. See our latest analysis for Stryker. For context, Stryker’s share price has been volatile around recent news, with a 4.17% 1 month share price return and a 5.88% decline year to date, while the 1 year total shareholder return is down 13.98%, the 3 year total shareholder return is up 23.40%, and...

Yahoo·08:11SYK▼−2.3%

Stryker Board Member Sold $117.78M In Company Stock

Ronda E Stryker, Board Member at Stryker (NYSE:SYK), reported an insider sell on August 20, according to a new SEC filing. What Happened: After conducting a thorough analysis, Stryker sold 350,000 shares of Stryker.

Benzinga·07:02SYK

Should Investors Buy STERIS as Growth Meets Reasonable Valuation?

STE enters fiscal 2027 with solid growth, recurring healthcare demand and better margins, but tariffs and investment needs temper the valuation case.

Yahoo·11:46

Enovis: Executing Better, But Still Remains Stuck In A Med-Tech No Man's Land

Enovis is gaining share in joint reconstruction, leveraging new products and capitalizing on competitor disruptions. Learn more about ENOV stock here.

SeekingAlpha·06:39

Disappointing Ortho Performance Continues To Hold Smith & Nephew Back (Downgrade)

Smith & Nephew stock is downgraded to 'Hold' amid weak orthopedics, a guidance cut, and exec turnover. Here's what you need to know about SNN.

SeekingAlpha·07:58

A Congress Member Bought Up To $60K In Amazon.com Stock: Here's What You Need To Know

Records from August 18, 2026 indicate that Representative Thomas Kean of New Jersey made a purchase of Amazon.com (NASDAQ:AMZN), valued between $4,004 and $60,000, with the transaction dated July 8, 2026 and filed in

Benzinga·07:00

Stryker Corporation: Hold For Quality, Wait For The Dip

Stryker is a MedTech compounder with 11% organic revenue growth and expanding margins. Click here to read why SYK stock is a Hold.

SeekingAlpha·21:17SYK▼−2.3%

Stryker (NYSE:SYK): A Quality Investment for Long-Term Investors

Stryker (SYK) passes the Caviar Cruise quality screen: strong growth, 36% ROIC, and solid cash conversion. A quality investing standout.

ChartMill·07:01SYK▼−2.3%

Wolfe Research Downgrades Stryker (SYK)

Fintel·03:22SYK▼−2.3%

Can Stryker (SYK) Still Look Undervalued After Backlog Recovery?

Stryker stock has delivered a 35.9% gain over the past five years, yet current checks suggest it is not an obvious bargain, even as an Intrinsic Value estimate using a Discounted Cash Flow (DCF) framework points to the shares trading below that intrinsic value by 19.8%. Stryker's 35.9% return over five years indicates the stock has rewarded long term holders. New investors now need to weigh valuation more carefully than during earlier stages of the move. Strong demand for Stryker's medical...

Yahoo·23:16SYK▼−2.3%